Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Queen's University at Kingston

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1841-10-16

Employees: 1K

Market Cap: -

Website: http://www.queensu.ca

Clinical Trials

Feasibility of an Interprofessional Rehabilitation Program for Chronic Low Back Patients in the Ethiopian Health Setting

Not Applicable

Not yet recruiting

Conditions: Chronic Low-back Pain

Interventions: Other: Interprofessional rehabilitation program
Other: Usual standard care

First Posted Date: 2023-05-19

Last Posted Date: 2023-05-19

Lead Sponsor: Queen's University

Target Recruit Count: 40

Registration Number: NCT05866146

Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients

Phase 4

Recruiting

Conditions: Critical Illness
New Onset Atrial Fibrillation

Interventions: Drug: Placebo
Drug: Magnesium sulfate

First Posted Date: 2023-04-25

Last Posted Date: 2024-11-14

Lead Sponsor: Dr. Stephanie Sibley

Target Recruit Count: 140

Registration Number: NCT05829317

Locations: 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada

PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma

Phase 2

Withdrawn

Conditions: Advanced Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Pembrolizumab
Drug: MET-4
Drug: Placebo

First Posted Date: 2023-02-24

Last Posted Date: 2023-05-18

Lead Sponsor: Canadian Cancer Trials Group

Registration Number: NCT05743777

Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: NSCLC

Interventions: Drug: JDQ443

First Posted Date: 2023-02-06

Last Posted Date: 2025-03-11

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 4

Registration Number: NCT05714891

Locations: 🇨🇦
BCCA - Vancouver, Vancouver, British Columbia, Canada
🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada

and more 6 locations

Structural Mitral Valve Project

Recruiting

Conditions: Mitral Regurgitation

First Posted Date: 2023-01-10

Last Posted Date: 2023-01-10

Lead Sponsor: Queen's University

Target Recruit Count: 30

Registration Number: NCT05678868

Locations: 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Phase 2

Recruiting

Conditions: Endometrial Cancer

Interventions: Radiation: Adjuvant radiotherapy (EBRT +/- brachytherapy)
Radiation: Vaginal brachytherapy
Other: Observation

First Posted Date: 2022-12-07

Last Posted Date: 2025-06-11

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 393

Registration Number: NCT05640999

Locations: 🇺🇸
Alaska Womens Cancer Care, Anchorage, Alaska, United States
🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 64 locations

RP-6306 in Patients With Advanced Cancer

Phase 2

Recruiting

Conditions: Advanced Cancer

Interventions: Drug: RP-6306
Drug: FOLFIRI Protocol
Drug: Trastuzumab
Drug: RP-3500
Drug: Gemcitabine

First Posted Date: 2022-11-04

Last Posted Date: 2025-03-11

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 78

Registration Number: NCT05605509

Locations: 🇨🇦
London Health Sciences Centre Research Inc., London, Ontario, Canada
🇨🇦
BCCA - Kelowna, Kelowna, British Columbia, Canada
🇨🇦
BCCA - Vancouver, Vancouver, British Columbia, Canada

and more 4 locations

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Other: Observation
Drug: RP-6306
Drug: Niraparib
Drug: Gemcitabine
Drug: Fulvestrant
Drug: RP-3500

First Posted Date: 2022-11-01

Last Posted Date: 2025-01-14

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 484

Registration Number: NCT05601440

Locations: 🇨🇦
Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇨🇦
BCCA - Kelowna, Kelowna, British Columbia, Canada
🇨🇦
BCCA - Vancouver, Vancouver, British Columbia, Canada

and more 7 locations

Be Outspoken and Overcome Stigmatizing Thoughts (BOOST) Group for Early Psychosis

Not Applicable

Active, not recruiting

Conditions: Schizophrenia
Psychosis

Interventions: Behavioral: Self-stigma intervention

First Posted Date: 2022-10-07

Last Posted Date: 2023-11-15

Lead Sponsor: Queen's University

Target Recruit Count: 100

Registration Number: NCT05571228

Locations: 🇨🇦
Queen's University, Kingston, Ontario, Canada

Ketogenic Diet Therapy Major Depressive Disorder

Not Applicable

Recruiting

Conditions: Major Depressive Disorder

Interventions: Other: ketogenic diet

First Posted Date: 2022-09-29

Last Posted Date: 2023-11-18

Lead Sponsor: Queen's University

Target Recruit Count: 10

Registration Number: NCT05558995

Locations: 🇨🇦
Queen's University - Kingston General Hospital, Kingston, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy